Introduction
============

The development of high resolution microarray and genome wide sequencing technologies allowed comprehensive characterization of mammalian transcriptomes. The main conclusion from the pioneering in-depth transcriptome studies performed by FANTOM (Functional Annotation Of Mouse genome) and ENCODE (Encyclopedia of DNA Elements) consortia was discovery of the pervasive transcription of the mouse and human genomes with protein coding mRNAs constituting only a minor fraction of the transcribed sequences ([@B71]; [@B9]; [@B6]). The most recent data from ENCODE consortium indicates that around 70% of human genome is transcribed, generating a vast range of noncoding RNAs ([@B16]). Based on transcript size noncoding RNAs are classified into small noncoding RNAs (\<200 nt) and long noncoding RNAs (lncRNAs; \>200 nt). Small noncoding RNAs, particularly miRNAs are well characterized as post-transcriptional regulators of mRNAs and have well established roles in cancer ([@B24]; [@B20]; [@B52]).

On the other hand, lncRNAs still remain poorly characterized, however, evidence for their importance and functionality is mounting. The number of known lncRNA genes is still rising as the process of their annotation is ongoing. The current version of GENCODE (encyclopedia of genes and gene variants) includes 15,877 human lncRNA genes encoding 26,414 transcripts based on manual curation, computational analysis, and experimental validation (Version 21, June 2014 freeze, GRCh38 -- Ensembl 77; [@B17]; [www.gencodegenes.org](http://www.gencodegenes.org)).

Long noncoding RNAs share common features with mRNAs, such as many of them are transcribed by RNA polymerase II, undergo splicing, polyadenylation, and 5′-capping (**Table [1](#T1){ref-type="table"}**). Similarly, to protein coding genes, lncRNA genes have histone marks of active promoters (H3K4me2/3, H2K9ac, H3K27ac) and actively transcribed gene bodies (H3K36me3; [@B32]; [@B15]). On the other hand, lncRNAs have several distinct features that distinguish them from protein coding mRNAs (**Table [1](#T1){ref-type="table"}**). LncRNAs generally lack or have very little open reading frames (ORFs). Commonly, lncRNA transcripts are shorter and have fewer exons. Unlike mRNAs, which are mostly transported to the cytoplasm, the majority of lncRNAs are localized to the nucleus ([@B15]). LncRNAs demonstrate relatively lower expression levels than protein coding genes, however, they exhibit more specific tissue expression patterns ([@B15]).

###### 

Comparison of several important features of mRNAs and long noncoding RNAs (lncRNAs) based on GENCODE v7 catalog of human transcripts\*.

  Feature                            mRNAs                lncRNAs
  ---------------------------------- -------------------- ----------------
  Median transcript length           2453 nt              592 nt
  Median number of exons             3                    8
  Expression levels                  Higher               Lower
  5' end supported by CAGE           55%                  15%
  3' end supported by polyA signal   51%                  39%
  Tissue specificity                 Lower                Higher
  Subcellular localization           Mostly cytoplasmic   Mostly nuclear

\*

The data shown in

Table

1

are taken from

Derrien et al. (2012)

.

Contrary to the initial view that lncRNAs might be a mere transcriptional noise, several lines of evidence indicate to their functionality ([@B76]). Firstly, many lncRNAs demonstrate clear signs of evolutionary conservation and selection ([@B75]; [@B32]). Secondly, expression of many lncRNAs is developmentally and temporally regulated and restricted to certain tissues ([@B11]; [@B82]; [@B67]). It is becoming increasingly clear that lncRNAs are important regulatory molecules acting at different levels of gene expression, such as chromatin remodeling, transcription, stability, posttranscriptional modifications, and translation. For example, lncRNAs Xist and HOTAIR (HOX transcript antisense RNA) recruit chromatin remodeling complexes, such as Polycomb repressive complex 2 (PRC2) to induce heterochromatin state, thus repressing gene expression at target loci ([@B117]; [@B30]; **Figure [1](#F1){ref-type="fig"}**). Indeed, a considerable proportion of lncRNAs has been shown to associate with PRC2 complex, implying that it might be one of the prevalent mechanisms for their functionality ([@B44]). LncRNAs directly regulate transcription by different mechanisms, such as via interaction with RNA binding proteins ([@B100]), repression of promoters ([@B63]), acting as co-activators of transcription factors ([@B22]), or negatively regulating transcription factors by sequestration ([@B48]; [@B40]). At the level of pre-mRNA processing, lncRNA MALAT1 can regulate alternative splicing by interacting with several serine/arginine (SR) splicing factors ([@B94]).

![**Model of long noncoding RNA (lncRNA) HOX transcript antisense RNA (HOTAIR) regulating expression of HOX genes in *trans***. LncRNA HOTAIR transcribed from the HOXC cluster of genes (chr. 2) binds PRC2 complex of polycomb-group of proteins and targets it to the HOXD cluster (chr. 12) leading to H3K27 methylation and silencing of neighboring HOXD genes. This figure is adapted from [@B85].](fgene-06-00145-g001){#F1}

Long noncoding RNAs can interact with mRNAs and modulate their translation both positively and negatively. For example, lincRNA-p21 interacts with JUNB and CTNNB1 mRNAs and selectively lowers their translation through a mechanism that includes reduced polysome sizes or ribosome 'drop-off' ([@B111]). In contrast, lncRNA antisense to Uchl1 gene increases translation of UCHL1 protein in a mechanism dependent on a 5′ overlapping sequence and an embedded inverted SINEB2 element in lncRNA ([@B10]). LncRNA can also regulate stability of target mRNAs through imperfect base pairing between an Alu element in the 3′ UTR of a Staufen 1 (STAU1)-mediated mRNA decay target and another Alu element in a cytoplasmic lncRNA ([@B28]). This imperfect base-pairing creates a lncRNA--mRNA duplex that binds STAU1 resulting in degradation of mRNA.

With the growing evidence of lncRNA functionality it is of no surprise that they are implicated in diverse pathologic conditions, including cancer. Various lncRNAs have been found to be differentially expressed in cancer and their enforced expression or knock down could result in altered phenotypical responses related to malignant transformation, such as changes in proliferation, invasive potential, or apoptosis. Similarly, to protein coding genes, lncRNAs can be classified into oncogenes and tumor suppressors. This opens opportunities for application of lncRNAs as biomarkers for cancer diagnosis and prognosis. Indeed, the functions of lncRNAs are more likely to correlate with their abundance as they do not encode proteins, making them highly suitable as biomarkers. In this review, we summarize the current knowledge about lncRNAs as potential diagnostic and prognostic biomarkers of cancer.

Diagnostic Cancer Biomarkers
============================

The tissue specific nature of expression of lncRNAs, which is generally higher than that of protein coding mRNAs ([@B15]), makes them potentially advantageous for identification of highly specific diagnostic biomarkers. Whereas some well known lncRNAs, such as HOTAIR are known to be deregulated in a wide spectrum of cancers, several lncRNAs have been described to be highly specific for a particular cancer type.

For example, expression of lncRNA PCA3 (Prostate Cancer Antigen 3) is highly restricted to prostate tissue ([@B8]). In the same study it was shown by differential display analysis that PCA3 is highly overexpressed in prostatic tumors in comparison with non-neoplastic prostatic tissue of the same patients. Moreover, its expression was not detected in other tumor types or cell lines ([@B8]). PCGEM1 is another lncRNA gene with highly prostate tissue-specific expression. Interestingly, its elevated expression was associated with high risk groups, such as the African--American population, which is more susceptible to prostate cancer as compared to Caucasian--American or those individuals with family history of prostate cancer as compared to those without family history ([@B74]). Another lncRNA, encoded in 8q24 locus reported to be associated with prostate cancer susceptibility in European and African--American populations, termed PRNCR1 (prostate cancer noncoding RNA 1), was shown to be up-regulated in some of the prostate cancer cells as well as precursor lesion prostatic intraepithelial neoplasia ([@B13]).

HULC (highly up-regulated in liver cancer) has been identified as highly up-regulated in hepatocellular carcinoma ([@B73]) and colorectal carcinomas that produce liver metastases but not in the primary colon tumors or their non-liver metastases ([@B64]). Interestingly, the specific genetic variant rs7763881 in HULC was found to be associated with decreased risk of HCC in persistent carriers of HBV ([@B59]).

Detection of cancer at the early stages significantly gnosis is the screening for biomarkers by non-invasive methods, such as sampling of extracellular fluids. A fraction of DNA and RNA molecules referred to as circulating nucleic acids (CNAs) are found in blood serum and other extracellular fluids. Changes in the levels of CNAs are associated with tumor burden and malignant progression, thus pointing to their potential as tumor biomarkers easily detected by PCR assays ([@B86]). Several lncRNAs have been characterized as potential biomarkers in human body fluids. The most prominent example of such biomarkers is PCA3, a lncRNA highly expressed is prostate cancer ([@B14]). The detection of PCA3 in the urine has been demonstrated to be a more specific marker to diagnose prostate cancer than the commonly used prostate-specific antigen (PSA) and already found wide application in clinics ([@B35]; [@B93]; [@B54]). Similarly, UCA1 (urothelial carcinoma associated 1) transcript detected in urine was shown to be a highly sensitive and specific biomarker of bladder carcinoma ([@B101]). HULC was detected with high frequency in plasma of patients with hepatocellular carcinoma, making it a promising diagnostic biomarker for this type of cancer ([@B105]). Several other studies identify promising biomarkers for different types of cancer, such as MALAT1 derived fragment detected in plasma as a biomarker for prostate cancer ([@B83]), AA174084 found in gastric juice as indicator of gastric cancer ([@B87]), a set of salivary lncRNAs as potential markers for oral squamous cell carcinoma diagnosis ([@B92]).

Exosomes are nanovesicles secreted into the extracellular environment from the cells upon fusion of intracellular vesicles with the plasma membrane ([@B81]). The molecular content of exosomes replicates that of the releasing cell and reflects its status. The abundance of exosomes in body fluids and possibility to detect tumor specific material of their parental cancer cells makes exosomes a promising tool for non-invasive diagnostics ([@B78]). The content of exosomes comprises different kinds of RNA, including lncRNAs ([@B42]). Indeed, lncRNAs are highly enriched in exosomes compared to donor cells ([@B3]; [@B27]). For example, lncRNA TUC339 was found to be highly enriched in extracellular vesicles secreted from hepatocellular carcinoma cells where it modulated tumor cell growth and adhesion ([@B50]). LincRNA--ROR, another lncRNA from hepatocellular carcinoma derived extracellular vesicles was shown to modulate chemotherapeutic response in this type of cancer ([@B91]). Given the fact that most transcriptome studies aimed to identify biomarkers were focused on miRNAs, shifting the focus to more unbiased characterization that would include other types of transcripts present in cancer derived exosomes would potentially lead to discovery of more lncRNA based biomarkers.

Prognostic Cancer Biomarkers
============================

Different lncRNAs were shown to be aberrantly expressed in cancer and correlate with tumorigenesis, tumor progression, and metastatic properties in various cancer conditions. Such lncRNA can be involved in both oncogenic and tumor suppressor pathways and their expression can correlate with good or bad prognosis, making them promising prognostic biomarkers (**Table [2](#T2){ref-type="table"}**).

###### 

lncRNAs with cancer biomarker potential.

  lnc-RNA        Cancer type               Reference                 Oncogene Tumor suppressor   Biomarker usability potential
  -------------- ------------------------- ------------------------- --------------------------- -----------------------------------------------------------------------
  HOTAIR         Breast                    [@B30], [@B5], [@B98]     Oncogene                    Predictor of metastasis and poor survival
                 Liver                     [@B26], [@B108], [@B41]   Oncogene                    Predictor of recurrence and poor survival
                 Colorectal                [@B49]                    Oncogene                    Predictor of liver metastasis and pool survival
                 Gastric                   [@B33]                    Oncogene                    Predictor of lymph node metastasis
                 Pancreas                  [@B46]                    Oncogene                    Predictor of poor survival
                 Lung                      [@B56], [@B70]            Oncogene                    Predictor of metastasis and poor survival
                 Esophagus                 [@B62]                    Oncogene                    Predictor of metastasis and poor survival
                 Cervical                  [@B38]                    Oncogene                    Predictor of metastasis and poor survival
  MALAT1         Lung adenocarcinoma       [@B43], [@B31]            Oncogene                    Predictor of metastasis and poor survival
                 Liver                     [@B53]                    Oncogene                    Predictor of recurrence after liver transplantation
                 Colorectal                [@B118]                   Oncogene                    Predictor of poor postoperative prognosis
                 Cervical                  [@B29]                    Oncogene                    
                 Bladder                   [@B110], [@B34]           Oncogene                    Predictor of metastasis
                 Uterine                   [@B107]                   Oncogene                    
                 Osteosarcoma              [@B21]                    Oncogene                    Predictor of poor response to chemotherapy
  H19            Esophagus                 [@B36]                    Oncogene                    
                 Breast                    [@B60]                    Oncogene                    
                 Lung                      [@B51]                    Oncogene                    
                 Bladder                   [@B1]                     Oncogene                    
                 Ovarian                   [@B45]                    Oncogene                    
                 Cervical                  [@B47]                    Oncogene                    
                 Osteosarcoma              [@B97]                    Oncogene                    
                 Neck squamous carcinoma   [@B18]                    Oncogene                    
                 Liver                     [@B65]                    Oncogene                    
  ncRAN          Neuroblastoma             [@B7], [@B112]            Oncogene                    Predictor of poor survival
                 Bladder                   [@B120]                   Oncogene                    
                 Colorectal                [@B79]                    Tumor suppressor            Low level predicts poor survival
  HULC           Liver                     [@B73], [@B64], [@B59]    Oncogene                    Diagnostics
  GAS5           Breast                    [@B68]                    Tumor suppressor            
                 Kidney                    [@B80]                    Tumor suppressor            
                 Pancreas                  [@B61]                    Tumor suppressor            
                 Bladder                   [@B57]                    Tumor suppressor            
                 Lung                      [@B88]                    Tumor suppressor            
                 Gastric                   [@B89]                    Tumor suppressor            Low level predicts poor prognosis
                 Pleural mesothelioma      [@B84]                    Tumor suppressor            Low level predicts poor prognosis
                 Liver                     [@B96]                    Tumor suppressor            Low level predicts poor prognosis
  PCA3           Prostate                  [@B8], [@B35]             Oncogene                    Non-invasive diagnosis by sampling urine or blood
                                                                                                 
                                                                                                 
                                           [@B93], [@B54]                                        
  UCA1           Bladder                   [@B101]                   Oncogene                    Non-invasive diagnosis by sampling urine
  PCGEM1         Prostate                  [@B74]                    Oncogene                    High risk predictor
  PRNCR1         Prostate                  [@B13]                    Oncogene                    High risk predictor
  MEG3           Leukemia                  [@B4]                     Tumor suppressor            CpG methylation predicts poor survival
                 Pituitary adenoma         [@B25]                    Tumor suppressor            
                 Meningioma                [@B114]                   Tumor suppressor            Loss associated with progression
                 Glioma                    [@B99]                    Tumor suppressor            
  NBAT-1         Neuroblastoma             [@B72]                    Tumor suppressor            Loss associated with progression
  LincRNA--ROR   Liver                     [@B91]                    Oncogene                    Diagnostics by sampling cancer exosomes; indicator of chemoresistance
  PCAT1          Prostate                  [@B77]                    Oncogene                    Associated with progression

HOTAIR is one of the most well studied examples of lncRNA implicated in cancer ([@B103]). Initially it was identified by [@B30] to be highly overexpressed in primary and metastatic breast cancer tissues as compared to normal breast epithelium. High HOTAIR expression level in primary tumors was shown to be a significant predictor of eventual metastasis and death ([@B30]). Enforced expression of HOTAIR in breast carcinoma cells induced genome wide retargeting of PRC2 and, as a result, altered H3K27 methylation and gene expression patterns, increased invasiveness, and metastasis ([@B30]). Interestingly, BRCA1, an important suppressor of breast cancer inhibits HOTAIR dependent PRC2 activity by competitive binding to its catalytic subunit EZH2 ([@B98]). In another breast cancer study it was shown that HOTAIR is regulated by oestradiol in estrogen receptor dependent manner ([@B5]).

HOTAIR was also shown to be involved in hepatocellular carcinoma ([@B26]; [@B108]; [@B41]). Overexpression of HOTAIR in tumor tissues was reported to be associated with increased risk of recurrence after hepatectomy, as well as positively correlate with lymph node metastasis ([@B26]). Similarly, increased HOTAIR was shown to be prognostic factor of tumor recurrence following liver transplantation ([@B108]). In the same study, knock down of HOTAIR in HCC cell line reduced cell viability and invasion, as well as increased sensitivity to cisplatin and doxorubicin ([@B108]). Patients with overexpressed HOTAIR had poorer prognoses and larger tumor sizes, more rapid proliferation of tumor cells ([@B41]).

In colorectal carcinoma high expression of HOTAIR was also shown to correlate with poor prognosis and liver metastasis ([@B49]). Positive correlation between expression levels of HOTAIR, the members of PRC2 complex, Suz12, and Ezh2, and H3K27me3 chromatin marks suggests the role of HOTAIR in PRC2 mediated chromatin reprogramming in metastasis ([@B49]). Apart from the primary tumors, HOTAIR was also shown to be a negative prognostic factor in the blood of colorectal patients suggesting that measuring the HOTAIR blood levels may provide a minimally invasive test to identify patients with unfavorable prognosis ([@B90]). High expression of HOTAIR associated with advanced stage, lymphatic node metastasis and poor survival was also reported in gastric cancer ([@B19]; [@B33]; [@B106]). The increased expression level of HOTAIR positively correlates with Suz12, implying PRC2 dependent mechanism of epigenetic reprogramming in oncogenicity of gastric carcinoma ([@B33]). Also HOTAIR was shown to act as an endogenous sponge of miR-331-3p miRNA, thus abolishing repression of its target HER2, implicated in development of gastric cancer ([@B58]). In addition to the above described, HOTAIR was reported to be a negative prognosis biomarker for a number of other malignancies, such as pancreatic cancer ([@B46]), lung cancer ([@B56]; [@B70]), esophageal carcinoma ([@B62]), cervical cancer ([@B38]), and colon cancer ([@B104]). A meta-analysis study of prognostic capability of HOTAIR in different types of cancer revealed that it is a more reliable predictor of overall survival in patients with digestive system malignancies ([@B113]).

Another paradigmal case of lncRNA based cancer biomarkers is MALAT1 (Metastasis-associated Lung Adenocarcinoma Transcript 1). As its name implies, it was discovered as a predictive marker of metastasis development in early stage lung adenocarcinoma ([@B43]). In a MALAT1 knockout model of human lung cancer cells it was shown that MALAT1 regulates metastatic signature of genes ([@B31]). In such model metastatic capacities of lung adenocarcinoma mouse xenografts were significantly compromised ([@B31]). In the same study, targeting MALAT1 with antisense nucleotides significantly reduced metastasis making it an interesting target for therapy ([@B31]).

In hepatocellular carcinoma (HCC) MALAT1 overexpression is a predictive factor for tumor recurrence following liver transplantation ([@B53]). The depletion of MALAT1 by siRNA in HepG2 cell line resulted in reduction of cell viability, mobility and invasiveness, as well as increase of sensitivity to apoptosis ([@B53]). High expression of MALAT1 was shown to be a marker of poor postoperative prognosis in colorectal carcinoma ([@B118]). Moreover, the obvious oncogenic role of MALAT1 was demonstrated in a number of other cancer models, including bladder cancer ([@B110]; [@B34]), cervical cancer ([@B29]), uterine sarcoma ([@B107]), and osteosarcoma ([@B21]).

H19 is lncRNA expressed from the maternal allele that plays an important role in genomic imprinting during growth and development ([@B23]). Loss of imprinting at the H19 locus in paternal allele results in biallelic expression and, therefore, elevated H19 levels in a wide range of cancers ([@B51]; [@B36]; [@B45]; [@B18]; [@B1]; [@B69]; [@B47]; [@B60]; [@B97]). High expression of H19 was shown to be associated with a range of risk factors, such as smoking, exposure to carcinogens and hypoxia ([@B65]). Indeed, hypoxia causes up-regulation of H19 in cell lines with mutated p53 ([@B66]). H19 is also directly induced by MYC oncogene in different cell lines ([@B2]). Further adding to the host of oncogenic pathways with the involvement of H19, it serves as a precursor of miR-675, miRNA that down-regulates RB1 tumor suppressor transcript in colorectal cancer ([@B95]).

NcRAN (noncoding RNA expressed in aggressive neuroblastoma) is encoded by a gene mapped to chromosome arm 17q, whose amplification is one of the most common genetic abnormalities associated with poor prognosis in neuroblastoma ([@B7]; [@B112]). Indeed, the high expression levels of ncRAN were significantly associated with poor prognosis of the neuroblastoma patients ([@B112]). In addition, ncRAN was found to be upregulated in bladder cancer as compared to normal tissues and confer a set of oncogenic properties, such as increased cell proliferation, migration, and invasion ([@B120]). In contrast, down-regulation of ncRAN was shown to be associated with metastatic properties and predict poor overall survival in colorectal carcinoma ([@B79]).

In addition to lncRNAs with pronounced oncogenic effects, which positively correlate with poor prognosis, a few lncRNAs have been characterized to act as tumor suppressors. One such example is GAS5 (growth arrest-specific 5), a tumor suppressor lncRNA which reduces growth, metabolism, and sensitizes cells to apoptosis by inhibiting glucocorticoid receptor ([@B48]). GAS5 is down-regulated in a number of cancers, such as breast cancer ([@B68]), renal cell carcinoma ([@B80]), pancreatic cancer ([@B61]), bladder cancer ([@B57]), non-small-cell lung cancer ([@B88]), gastric cancer ([@B89]), malignant pleural mesothelioma ([@B84]), hepatocellular carcinoma ([@B96]). Low level of GAS5 indicates a poor prognosis in cancer patients ([@B89]; [@B96]).

Another example of a tumor suppressor lncRNA is lincRNA-p21. This lncRNA was shown to be directly induced by p53 and play a crucial role in p53 mediated transcriptional response ([@B39]). Maternally expressed gene 3 (MEG3) is another prominent tumor suppressor lncRNA that acts by increasing p53 activity on specific transcription targets ([@B119]). Besides, MEG3 is able to inhibit cell proliferation in the absence of p53 suggesting that this lncRNA may act also via p53-independent pathway ([@B119]). Consistently, MEG3 is down-regulated in a number of cancers, including myeloid leukemia ([@B4]), pituitary adenoma ([@B25]), meningioma ([@B114]), and glioma ([@B99]).

In conclusion, lncRNAs may act both as oncogenes and tumor suppressors without obvious prevalence of one class over another. In this respect lncRNAs behave similarly, to protein-coding transcripts.

Prognostic Expression Signatures Based on lncRNAs
=================================================

Characterizing tumor transcriptomes at the system's level allows identification of molecular subtypes of cancer and development of predictive and prognostic gene expression signatures. Microarrays have been widely used for the past two decades in preclinical research to characterize tumor gene expression profiles on a genome-wide scale. Most of these signatures were based on protein coding genes as little was known about lncRNAs and their important roles in cancer. However, the widely used commercial microarray platforms in addition to protein coding mRNAs were designed to detect numerous ESTs and non-annotated RNAs. Many of these transcripts are now annotated as *bona fide* lncRNAs, therefore the vast collection of microarray datasets accumulated during the past two decades provides a valuable resource for identification of novel gene expression signatures and biomarkers based on lncRNAs. In our recent study we annotated probe sets detecting lncRNAs on widely used Affymetrix U133 series of microarray platforms by using two approaches: firstly by matching probe sets to Gencode database of lncRNAs and secondly by developing a stringent *in silico* protein coding potential prediction filter ([@B109]). Affymetrix U133 microarrays have been found to contain probe sets for the measurement of 1581 lncRNAs ([@B109]). Using this resource and previously deposited microarray-based data on expression profiling of neuroblastic tumors we identified 159 lncRNA signature that discriminates between localized and metastatic stages of neuroblastoma, as well as between relapsing and non-relapsing primary tumors ([@B109]). The data mining of Affymetrix U133 Plus datasets was also applied to identify lncRNA signatures associated with different histological subtypes and malignancy grades of glioma ([@B116]). In the follow up study, the six-lncRNA prognostic signature of glioma significantly associated with overall survival was identified ([@B115]). In another study the classification of glioma into three molecular subtypes based on lncRNA expression profiles was proposed ([@B55]). Similarly, using lncRNA mining approach, [@B37] identified six lncRNA prognostic signature significantly associated with disease free survival in colorectal carcinoma. LncRNA-based expression profiles were also utilized to classify colorectal cancer samples into five distinct molecular subtypes, each characterized by distinct biological pathways and clinical outcome ([@B12]).

As high throughput sequencing technology becomes cheaper and more accessible we might expect the influx of *de novo* data from transcriptome sequencing and identification of new biomarkers and diagnostic signatures. For example, [@B77] utilized RNA-Seq approach to identify 121 lncRNAs associated with prostate cancer progression in a cohort of 102 patients. One of these lncRNAs PCAT-1 was further characterized as a regulator of proliferation in prostate cancer cells ([@B77]). In a similar study the sequencing of transcriptomes of high and low risk neuroblastoma identified a set of differentially expressed lncRNAs. One of them NBAT-1 was characterized as a tumor suppressor, whose loss contributes to aggressive neuroblastoma by increasing proliferation and impairing differentiation ([@B72]). RNA-Seq analysis was also employed by [@B102] to detect lncRNAs associated with lung cancer. In this study the transcriptome sequencing data from a cohort of 567 patients were used to identify 111 novel lncRNAs differentially regulated between tumor and adjacent normal tissue samples. Further meta-analysis revealed that a subset of these lncRNAs was deregulated in a broad range of tumors and another subset was highly deregulated specifically in lung cancers, making the latter a promising source of biomarkers ([@B102]).

Concluding Remarks
==================

The last decade witnessed a vast expansion of knowledge regarding lncRNAs and their important roles in regulation of various biological processes and development of disease. A number of lncRNAs, such as HOTAIR, MALAT and H19 were found to be aberrantly expressed in a number of cancers and extensively characterized as important players affecting the hallmark events of carcinogenesis, such as proliferation, apoptosis, and metastasis. These examples demonstrate that lncRNAs, on par with protein coding genes and miRNAs, have a great potential to be used as cancer biomarkers. Indeed, since lncRNAs are implicated in cancer biology at the level of RNA unlike mRNAs, which represent an intermediate on the way to functioning protein, their levels of expression are more likely to correlate with cancer phenotypes. Also, since proteins and lncRNAs represent different regulatory realms, their combination might increase each other's power as diagnostic and prognostic tools. It should be noted that the few examples described in this review are just a tip of the iceberg, as the field of lncRNAs is currently evolving and the work of annotation and characterization of lncRNAs is ongoing. With the deep sequencing technology becoming cheaper and more accessible one might expect an explosive growth of newly identified lncRNAs differentially expressed in cancers and associated with various clinical parameters.
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